Related Experiment Video
Updated: Jan 16, 2026
08:16
Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
Published on: March 4, 2014
33.1K
Disabilities and Handicaps of Patients with Laron Syndrome
1Schneider Children's Medical Center, Petah Tikva, Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv-Yafo 6997801, Israel.
Children (Basel, Switzerland)
|September 27, 2025
Summary
Laron Syndrome (LS), a rare dwarfism caused by inactive growth hormone receptor, leads to severe health issues like obesity and diabetes. Early IGF-I treatment can prevent and reverse these debilitating symptoms, improving patients' quality of life.
Area of Science:
- Endocrinology
- Genetics
- Metabolic Disorders
Background:
- Laron Syndrome (LS) is a rare hereditary dwarfism linked to GH-Receptor gene mutations.
- It results in inactive growth hormone (GH) and low Insulin-like Growth Factor I (IGF-I) levels.
- LS affects diverse populations globally, with notable occurrences in specific ethnic groups.
Purpose of the Study:
- To document the spectrum of disabilities and handicaps in Laron Syndrome patients.
- To analyze the impact of LS on patients from infancy through adulthood.
- To evaluate the long-term consequences of IGF-I deficiency.
Main Methods:
- Longitudinal study of 76 Laron Syndrome patients.
- Assessment of growth, social achievements, and life difficulties.
- Monitoring of somatic and biochemical changes over time.
Main Results:
- Longstanding IGF-I deficiency causes progressive disabilities including dwarfism, obesity, diabetes, fatty liver, and cardiovascular issues.
- Neurological and orthopedic problems are common, impacting vocational training, occupation, and social life.
- These complications significantly reduce the Quality of Life (QoL) for LS patients.
Conclusions:
- Early IGF-I replacement therapy is crucial for managing Laron Syndrome.
- Initiating treatment early can prevent and reverse symptoms of IGF-I deficiency.
- Timely intervention improves patient outcomes and quality of life.
Related Concept Videos
01:22Lysosomal Hydrolases
4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K
01:25Learning Disabilities
575
Learning disabilities are cognitive disorders caused by neurological impairments that affect cognitive functions like language and reading, without indicating overall intellectual or developmental challenges. These disabilities differ from global intellectual or developmental disabilities as they are limited to distinct cognitive functions. Common learning disabilities include dysgraphia, dyslexia, and dyscalculia, each of which impacts unique aspects of learning.
Dyslexia
Dyslexia is a...
Dyslexia
Dyslexia is a...
575
01:20Inborn Errors of Metabolism
697
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
697
01:29Intellectual Disability
641
Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
641
01:27Glucose Transporters
27.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.2K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
256
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
256